Zhengbin Yao - Apr 4, 2023 Form 4 Insider Report for NexImmune, Inc. (NEXI)

Role
Director
Signature
/s/ John Rudy, attorney-in-fact
Stock symbol
NEXI
Transactions as of
Apr 4, 2023
Transactions value $
$0
Form type
4
Date filed
4/6/2023, 08:37 PM
Previous filing
Jun 15, 2022
Next filing
Jul 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEXI Stock Option (right to buy) Disposed to Issuer -61.7K -100% 0 Apr 4, 2023 Common Stock 61.7K $1.82 Direct F1
transaction NEXI Stock Option (right to buy) Award +61.7K 61.7K Apr 4, 2023 Common Stock 61.7K $1.64 Direct F1
transaction NEXI Stock Option (right to buy) Disposed to Issuer -9.56K -100% 0 Apr 4, 2023 Common Stock 9.56K $17.00 Direct F2
transaction NEXI Stock Option (right to buy) Award +9.56K 9.56K Apr 4, 2023 Common Stock 9.56K $1.64 Direct F2
transaction NEXI Stock Option (right to buy) Disposed to Issuer -23.1K -100% 0 Apr 4, 2023 Common Stock 23.1K $4.31 Direct F3
transaction NEXI Stock Option (right to buy) Award +23.1K 23.1K Apr 4, 2023 Common Stock 23.1K $1.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Yao's continued service on such vesting date.
F2 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested.
F3 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested.